Intravenous injection of cyclosporin A loaded lipid nanocapsules fights inflammation and immune system activation in a mouse model of diabetic retinopathy.
Cyclosporin A
Diabetic retinopathy
Drug delivery
Intravenous nanotherapy
Lipid nanocapsules
RPE
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
accepted:
11
04
2023
medline:
3
10
2023
pubmed:
20
5
2023
entrez:
19
5
2023
Statut:
ppublish
Résumé
Inflammation and immune system activation are key pathologic events in the onset and escalation of diabetic retinopathy (DR). Both are driven by cytokines and complement originating from the retinal pigment epithelium (RPE). Despite the RPE's pivotal role, there is no therapeutic tool to specifically interfere with the RPE-related pathomechanism. A therapy that addresses RPE cells and counteracts inflammation and immune response would be of paramount value for the early treatment of DR, where currently are no specific therapies available. Here, we utilized lipoprotein-mimetic lipid nanocapsules to deliver the anti-inflammatory and immunosuppressive drug cyclosporin A (CsA) to RPE cells. Using a mouse model of DR that mirrors all pathologic aspects of human DR, we demonstrate that intravenously applied CsA-loaded lipid nanocapsules comprehensively counteract inflammation and immune system activation. One single injection suppressed the expression of pro-inflammatory cytokines, dampened macrophage infiltration, and prevented macrophage and microglia activation in eyes with DR. This work shows that CsA-loaded lipid nanocapsules can offer new avenues for the treatment of DR.
Identifiants
pubmed: 37208562
doi: 10.1007/s13346-023-01350-7
pii: 10.1007/s13346-023-01350-7
pmc: PMC10545584
doi:
Substances chimiques
Cyclosporine
83HN0GTJ6D
Nanocapsules
0
Cytokines
0
Lipids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2807-2818Informations de copyright
© 2023. The Author(s).
Références
J Neurosci. 2002 May 15;22(10):3987-93
pubmed: 12019318
Diabetes. 2011 Jan;60(1):9-16
pubmed: 21193734
Lancet Diabetes Endocrinol. 2019 Feb;7(2):140-149
pubmed: 30005958
Prog Retin Eye Res. 2001 Jan;20(1):29-48
pubmed: 11070367
Vision Res. 2017 Oct;139:115-122
pubmed: 28583293
Cell Commun Signal. 2004 Jun 2;2(1):3
pubmed: 15175101
Kidney Int. 2000 Jul;58(1):123-30
pubmed: 10886556
PLoS One. 2009;4(4):e5149
pubmed: 19340291
Prog Retin Eye Res. 2011 Sep;30(5):343-58
pubmed: 21635964
JAMA. 2007 Aug 22;298(8):902-16
pubmed: 17712074
Prog Retin Eye Res. 2017 Mar;57:134-185
pubmed: 28028001
Drug Discov Today. 2022 Sep;27(9):2497-2509
pubmed: 35654389
Exp Eye Res. 2007 May;84(5):812-22
pubmed: 17331500
Am J Pathol. 2015 Jun;185(6):1749-68
pubmed: 25857227
FASEB J. 2002 Mar;16(3):438-40
pubmed: 11821258
Am J Pathol. 2017 Nov;187(11):2570-2589
pubmed: 28823871
Exp Diabetes Res. 2007;2007:95103
pubmed: 18274606
Sci Adv. 2022 Sep 23;8(38):eabo6638
pubmed: 36149956
Br J Ophthalmol. 2002 Apr;86(4):363-5
pubmed: 11914197
Diabetes Obes Metab. 2011 Sep;13(9):784-90
pubmed: 21535345
N Engl J Med. 2012 Mar 29;366(13):1227-39
pubmed: 22455417
Br J Ophthalmol. 2015 Feb;99(2):220-6
pubmed: 25193672
Br J Ophthalmol. 2000 Jul;84(7):736-40
pubmed: 10873985
Clin Transplant. 1999 Aug;13(4):356-62
pubmed: 10485379
J Drug Target. 2017 Jun;25(5):386-405
pubmed: 28122462
PLoS One. 2011;6(9):e24793
pubmed: 21969860
Transpl Int. 2005 May;18(5):619-22
pubmed: 15819813
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
Curr Eye Res. 2012 May;37(5):416-20
pubmed: 22409294
Physiol Rev. 2005 Jul;85(3):845-81
pubmed: 15987797
Nat Rev Drug Discov. 2016 Jun;15(6):385-403
pubmed: 26775688
Eur J Pharmacol. 2016 Sep 15;787:94-104
pubmed: 26948311
J Endocrinol Invest. 2017 Sep;40(9):925-935
pubmed: 28357783